NCT02689271

CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 365 (actual)
• Sponsor: University College, London · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To enable the paradigm of mp-MRI before biopsy in all patients with suspected prostate cancer by better selecting patients who will benefit from diagnostic MRI and by improving the performance of the mp-MRI itself

Detailed description

Patients will undergo an advanced diffusion-weighted MRI sequence called VERDICT with the intention of better characterising prostate cancer. A panel of serum and urine biomarkers will also be analysed, which we hope will predict those patients who go on have a positive MRI. OBJECTIVES: * To establish a fluidic marker - prostate MRI paradigm which: (i) utilises fluidic markers to rationalise selection of patients with significant prostate cancer; and (ii) improves the diagnostic accuracy of imaging over and above standard multiparametric (mp) MRI * Enable a pathway for rapid clinical evaluation of emerging fluidic markers and exosomes * Assess the repeatability of VERDICT MRI * Ascertain whether VERDICT derived quantitative parameters correlate with quantitative histological parameters * Develop a database of fluidic marker and VERDICT characterised, mp-MRI, histologically validated patients for subsequent exploratory and longitudinal outcome analysis

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
OTHER	MRI	VERDICT diffusion-weighted microstructure imaging sequence

Timeline

• Start date: 2016-04-01
• Primary completion: 2019-12-01
• Completion: 2019-12-01
• First posted: 2016-02-23
• Last updated: 2020-03-27

Locations

1 site across 1 country: United Kingdom